Journal of Maxillofacial and Oral Surgery

, Volume 17, Issue 4, pp 597–610 | Cite as

Co-delivery of 5-Fluorouracil and Curcumin Nanohybrid Formulations for Improved Chemotherapy Against Oral Squamous Cell Carcinoma

  • Saurabh Srivastava
  • Shadab MohammadEmail author
  • Aditya Bhushan Pant
  • Prabhat Ranjan Mishra
  • Gitu Pandey
  • Shalini Gupta
  • Sana Farooqui
Original Article



The chemotherapeutics agent, 5-fluorouracil (5-FU), and curcumin (Cur), a natural antioxidant, has a wide pharmacological window to treat oral carcinoma; however, both drugs have limited bioavailability. This research study designs to develop a nanoemulsions (NEs) formulation by combining 5-FU and Cur to improve anticancer activity against oral cavity squamous cell carcinoma (OSCC) cells from the diversified origin for in vitro analysis, SCC090 (human tongue) and SCC152 (human hypo-pharynx).


NEs formulated through homogenization, applying high-energy ultrasonication technique. The prepared 5-FUNE/Cur-NE/5-FU-Cur-NE were characterized and optimized by different in vitro assays to evaluate release system and treatment of OSCC cells to monitor cellular acceptability, such as in vitro anticancer activity by MTT assay, cell uptake studies and protein expression associated apoptotic study.


5-FUNE/Cur-NE/5-FU-Cur-NE successfully formulated and show mean-value of the particle size (150–200 nm), surface charge (− 25.70 to − 37.91 mV), and PDI (0.194). In vitro release of 5-FUNE/Cur-NE/5-FU-Cur-NEs was monitored over a course of 04 days, where acidic pH shows higher release as compared to alkaline pH, along with acceptable stability data. Cytotoxicity study has shown higher-dose-dependent anticancer effect with a reduced IC50 value of NEs as compared to BLNE. Cellular uptake study of 5-FUNE/Cur-NE/5-FU-Cur-NEs upgraded many folds, comparatively BLNE and show potential cell arrest. Additionally, the cell protein (Blc2, Bax, P53, and P21) expression was revised and raised cell apoptosis.


The combinational loaded, 5-FU and Cur in nanoformulation system have proven their potency to deliver improved anticancer activity, against oral cancer.


5-Fluorouracil Curcumin Oral cancer Nanoparticles Drug Delivery 



The author, Saurabh Srivastava, is very grateful to Indian Council of Medical Research (ICMR), New Delhi, India (Project id-45/21/2013-NAN-BMS), for providing the fellowship grant to conduct his Ph.D. work.

Compliance with Ethical Standards

Conflict of interest

All the authors declared no conflicts of interest in this research work for the publication.


  1. 1.
    Aktipis CA, Boddy AM, Jansen G, Hibner U, Hochberg ME, Maley CC, Wilkinson GS (2015) Cancer across the tree of life: cooperation and cheating in multicellularity. Philos Trans R Soc Lond B Biol Sci 370(1673):1–21. CrossRefGoogle Scholar
  2. 2.
    Siegel RL, Miller KD, Jemal A (2017) Cancer statistics, 2017. CA Cancer J Clin 67:7–30. CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Karnov KKS, Gronhoj C, Jensen DH, Wessel I, Charabi BW, Specht L, Kjaer A, von Buchwald C (2017) Increasing incidence and survival in oral cancer: a nationwide Danish study from 1980 to 2014. Acta Oncol 56:1204–1209. PubMedCrossRefGoogle Scholar
  4. 4.
    Takiar R, Nadayil D, Nandakumar A (2010) Projections of number of cancer cases in India (2010–2020) by cancer groups. Asian Pac J Cancer Prev 11(4):1045–1049PubMedGoogle Scholar
  5. 5.
    Tapia JL, Goldberg LJ (2011) The challenges of defining oral cancer: analysis of an ontological approach. Head Neck Pathol 5(4):376–384. PubMedPubMedCentralCrossRefGoogle Scholar
  6. 6.
    Chinn SB, Myers JN (2015) Oral cavity carcinoma: current management, controversies, and future directions. J Clin Oncol 33(29):3269–3276. PubMedPubMedCentralCrossRefGoogle Scholar
  7. 7.
    Bundela S, Sharma A, Bisen PS (2015) Potential compounds for oral cancer treatment: resveratrol, nimbolide, lovastatin, bortezomib, vorinostat, berberine, pterostilbene, deguelin, andrographolide, and colchicine. PLoS ONE 10(11):1–31. CrossRefGoogle Scholar
  8. 8.
    Ratajczak MZ, Jadczyk T, Schneider G, Kakar SS, Kucia M (2013) Induction of a tumor-metastasis-receptive microenvironment as an unwanted and underestimated side effect of treatment by chemotherapy or radiotherapy. J Ovarian Res 6(95):2–9. CrossRefGoogle Scholar
  9. 9.
    Sun J, Wei Q, Zhou Y, Wang J, Liu Q, Xu H (2017) A systematic analysis of FDA-approved anticancer drugs. BMC Syst Biol 11(87):27–43. CrossRefGoogle Scholar
  10. 10.
    Arias JL (2008) Novel strategies to improve the anticancer action of 5-fluorouracil by using drug delivery systems. Molecules 13(10):2340–2369PubMedCrossRefGoogle Scholar
  11. 11.
    Safarzadeh E, Sandoghchian Shotorbani S, Baradaran B (2014) Herbal medicine as inducers of apoptosis in cancer treatment. Adv Pharm Bull 4(1):421–427. PubMedPubMedCentralCrossRefGoogle Scholar
  12. 12.
    Pavan AR, Silva GD, Jornada DH, Chiba DE, Fernandes GF, Man Chin C, Dos Santos JL (2016) Unraveling the anticancer effect of curcumin and resveratrol. Nutrients 8(11):628–678. PubMedCentralCrossRefGoogle Scholar
  13. 13.
    Wan S, Sun Y, Qi X, Tan F (2012) Improved bioavailability of poorly water-soluble drug curcumin in cellulose acetate solid dispersion. AAPS PharmSciTech 13(1):159–166. PubMedCrossRefGoogle Scholar
  14. 14.
    Gao Z, Li Z, Yan J, Wang P (2017) Irinotecan and 5-fluorouracil-co-loaded, hyaluronic acid-modified layer-by-layer nanoparticles for targeted gastric carcinoma therapy. Drug Des Devel Ther 11:2595–2604. PubMedPubMedCentralCrossRefGoogle Scholar
  15. 15.
    Zhang RX, Wong HL, Xue HY, Eoh JY, Wu XY (2016) Nanomedicine of synergistic drug combinations for cancer therapy - Strategies and perspectives. J Control Release 240:489–503. PubMedPubMedCentralCrossRefGoogle Scholar
  16. 16.
    Pangeni R, Choi SW, Jeon OC, Byun Y, Park JW (2016) Multiple nanoemulsion system for an oral combinational delivery of oxaliplatin and 5-fluorouracil: preparation and in vivo evaluation. Int J Nanomedicine 11:6379–6399. PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Borhade V, Pathak S, Sharma S, Patravale V (2012) Clotrimazole nanoemulsion for malaria chemotherapy. Part II: stability assessment, in vivo pharmacodynamic evaluations and toxicological studies. Int J Pharm 431(1–2):149–160. PubMedCrossRefGoogle Scholar
  18. 18.
    Wang ZQ, Liu K, Huo ZJ, Li XC, Wang M, Liu P, Pang B, Wang SJ (2015) A cell-targeted chemotherapeutic nanomedicine strategy for oral squamous cell carcinoma therapy. J Nanobiotechnol 13(63):1–10. CrossRefGoogle Scholar
  19. 19.
    Indran IR, Tufo G, Pervaiz S (1807) Brenner C (2011) Recent advances in apoptosis, mitochondria and drug resistance in cancer cells. Biochim Biophys Acta 6:735–745. CrossRefGoogle Scholar
  20. 20.
    Russo A, Maiolino S, Pagliara V, Ungaro F, Tatangelo F, Leone A, Scalia G, Budillon A, Quaglia F, Russo G (2016) Enhancement of 5-FU sensitivity by the proapoptotic rpL3 gene in p53 null colon cancer cells through combined polymer nanoparticles. Oncotarget 7(48):79670–79687. PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    Tuomela A, Hirvonen J, Peltonen L (2016) Stabilizing Agents for Drug Nanocrystals: effect on Bioavailability. Pharmaceutics 8(2):1–18. CrossRefGoogle Scholar
  22. 22.
    Monteiro LM, Lione VF, do Carmo FA, do Amaral LH, da Silva JH, Nasciutti LE, Rodrigues CR, Castro HC, de Sousa VP, Cabral LM (2012) Development and characterization of a new oral dapsone nanoemulsion system: permeability and in silico bioavailability studies. Int J Nanomedicine 7:5175–5182. PubMedPubMedCentralCrossRefGoogle Scholar
  23. 23.
    Kim TH, Lee GJ, Kang JH, Kim HJ, Kim TI, Oh JM (2014) Anticancer drug-incorporated layered double hydroxide nanohybrids and their enhanced anticancer therapeutic efficacy in combination cancer treatment. Biomed Res Int 2014:1–11. CrossRefGoogle Scholar
  24. 24.
    Unciti-Broceta JD, Cano-Cortes V, Altea-Manzano P, Pernagallo S, Diaz-Mochon JJ, Sanchez-Martin RM (2015) Number of nanoparticles per cell through a spectrophotometric method: a key parameter to assess nanoparticle-based cellular assays. Sci Rep 5:10091. PubMedPubMedCentralCrossRefGoogle Scholar
  25. 25.
    Vranic S, Boggetto N, Contremoulins V, Mornet S, Reinhardt N, Marano F, Baeza-Squiban A, Boland S (2013) Deciphering the mechanisms of cellular uptake of engineered nanoparticles by accurate evaluation of internalization using imaging flow cytometry. Part Fibre Toxicol 10(2):1–16. CrossRefGoogle Scholar

Copyright information

© The Association of Oral and Maxillofacial Surgeons of India 2018

Authors and Affiliations

  • Saurabh Srivastava
    • 1
  • Shadab Mohammad
    • 1
    Email author
  • Aditya Bhushan Pant
    • 2
  • Prabhat Ranjan Mishra
    • 3
  • Gitu Pandey
    • 3
  • Shalini Gupta
    • 4
  • Sana Farooqui
    • 1
  1. 1.Department of Oral and Maxillofacial SurgeryKing George’s Medical UniversityLucknowIndia
  2. 2.In Vitro Toxicology LaboratoryCSIR-Indian Institute of Toxicology ResearchLucknowIndia
  3. 3.Pharmaceutics DivisionCSIR-Central Drug Research InstituteLucknowIndia
  4. 4.Department of Oral Pathology and MicrobiologyKing George’s Medical UniversityLucknowIndia

Personalised recommendations